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The Overall Scene
Cystic echinococcosis (CE), an infection
with the larval form of the dog tapeworm
Echinococcus granulosus, still causes serious
lung and liver disease with a worldwide
geographical distribution. This parasitic
infection is preventable, eliminable, and
treatable—in theory. The biological cycle
can be attacked at various points: regular
dog deworming, controlled sheep slaugh-
tering, vaccination of the intermediate
(sheep) animal host, and possibly in the
future, vaccination of the definitive (dog)
animal host (Figure 1). However, breaking
the cycle in practice is difficult and
requires long-lasting efforts. Control pro-
grams are expensive to set up and sustain.
With the currently available options, a
period of 20 years is needed to reach
elimination, a goal that, unsurprisingly,
has only been reached in rich countries
[1].
At the current pace of control, patients
suffering from CE will be seen for many
decades to come. CE disease is chronic,
complex, and neglected [2–4]. It is still
poorly understood, and recommendations
for diagnosis and treatment have not
progressed beyond expert opinions and
are not necessarily adopted by clinicians
because of lack of grade I evidence.
The critical issues are:
(1) CE may develop silently over years
and even decades until it surfaces with
signs and symptoms or as a chance
finding on an ultrasound (US) scan or
chest X-rays requested for unrelated
reasons. Clinical manifestations may
mean that the cyst is already compli-
cated, e.g., ruptured into the biliary or
bronchial tree, secondarily infected
with bacteria, or leaking and causing
allergic reactions if not anaphylactic
shock.
(2) Screening large samples of popula-
tions to detect asymptomatic cases is
expensive. As with all screening pro-
cedures, ethical issues arise: do all
patients in whom cysts are found
require treatment? Is the treatment
which we then offer well established
and safe? And is it available at all?
Screening projects in endemic areas
are often inadequately prepared, as
the clinical management is not pro-
vided locally for those who are found
positive.
Problems start with the screening tool.
With the exception of liver US, the
available methods are far from satisfacto-
ry. In regards to serology, the sensitivity
and specificity of several antigens have
been well defined [5,6], but available
assays still lack standardization, sensitivity,
and specificity [7]. Controversies on the
usefulness for clinical diagnosis and
screening remain unresolved [8]. Serodi-
agnostic performance depends on several
factors, such as cyst location, cyst stage,
and even cyst size, but these and other
variables have not been thoroughly assess-
ed to date.
Ultrasound is an indispensable tool, but
will likely miss very small cysts, and its
efficacy is mostly restricted to intraabdom-
inal organs. Additionally, some cyst stages
may be difficult to distinguish from non-
parasitic cysts, which are common. The
problem continues when an echinococcal
cyst has been diagnosed. In settings where
health care facilities are several days of
travel away from the rural areas where
patients live and work, and as long as we
have doubts on what the natural evolution
of their cysts will be, clinical decision
making is difficult. It has to be done in
each case individually based on current
standards, clinicians’ experience, and local
technical possibilities, supported by em-
barrassingly poor evidence.
(3) Not all CE patients are similar, even
at a population level. Broadly speak-
ing, there are two defined groups of
patients, each with a different set of
problems: mainly asymptomatic pa-
tients (detected in screening programs
or by chance), or clinically apparent
cases (mostly patients with complicat-
ed cysts).
(a) Patients with cysts detected during screening
activities or as a chance finding. They mostly
receive the treatment with which the
attending clinician is familiar. This is not
necessarily the best option relative to the
cyst stage and clinical situation of the
patient. Preliminary results from a survey
on knowledge, attitudes, and practices
regarding clinical management of CE in
European, North African, and Middle
Eastern countries yielded alarming results
[9]. Patients may be put at risk of
interventions that may be completely
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sizeable number of cysts that have become
inactive and do not cause any symptoms
or complications.
A significant proportion of cysts stop
growing and follow a path to spontaneous
involution. Long-term follow-up suggests
that these cysts and the patients harbour-
ing them should be left alone. This is an
appealing perspective for patients and
health services, if evidence can be gath-
ered in its support. CE4 and CE5 cysts
appear to be very good candidates for this
approach if they do not compromise any
vital structures. It is, however, unclear if
and under which circumstances this con-
cept can be extended to other cyst types.
(b) Patients developing complications. Suc-
cessful management depends on equip-
ment, skills, and quality of available health
services. The most common complications
are biliary obstruction with or without
cholangitis, bronchial obstruction, bacteri-
al infection of the cyst cavity with abscess
formation, rupture with anaphylactic re-
actions that range from mild to lethal
anaphylactic shock, secondary echinococ-
cosis (growth of new cysts caused by
seeding of protoscolices, generally in a
cavity such as the peritoneal space)
following spillage of fluid from a cyst that
ruptured either spontaneously or because
of a therapeutic maneuver, and impaired
function of organs and blood vessels
compressed by growing adjacent cysts
(Figure 2). In most endemic countries,
the required setup is only met in major
cities a long way off from where patients
experiencing complications live.
What Is Available Today to
Diagnose and Treat CE
Patients?
Ultrasound is well established as a tool
to diagnose, stage, and follow up CE cysts
in the liver and other locations. Gharbi
and colleagues developed the first widely
adopted US classification in 1981 [10].
Other classifications were subsequently
produced but were not as widely used. In
1994, the World Health Organization
(WHO)-Informal Working Group started
developing an international standardised
US classification that could be universally
applied to replace the plethora of classifi-
cations previously used (Figure 3) [11].
Even with all the obvious advantages of a
standardised classification, some impor-
tant issues still need to be resolved, one
being the right sequence of cyst stages seen
as the effect of natural or treatment-
induced involution. A recent assessment
of metabolic profiles of cyst stages with
high-field proton magnetic resonance
spectroscopy (
1H MRS) has shown that
the WHO IWGE classification of active,
inactive, and transitional stages is perfectly
in line with the metabolic activity profiles
of the cysts, with the exception of CE3b,
which appears vigorously active in
1H
MRS, a finding that corresponds well with
clinical experience [12]. US has been
confirmed as an invaluable tool to assess
cysts both with respect to viability and
potential complications (Figure 2).
There are basically four management
options: surgery, percutaneous sterilization
techniques, anti-parasitic treatment, and
observation (‘‘watch & wait’’). Their indi-
vidual roles were recently reviewed [2–4].
Each of the four strategies certainly has its
place, but the specific places and bound-
aries are still not well defined.
Surgery, the oldest form of treatment,
keeps its place in most of the complicated
forms of the disease. There is some
competition between surgery and percu-
taneous approaches, in particular modified
catheterization techniques, to be resolved,
but this comparison requires carefully
designed studies and cannot be decided
on the basis of exclusively non-compara-
tive small clinical studies, which are the
only ones currently available.
Proponents of classical PAIR (punction,
aspiration, injection, reaspiration) [13]
have lost a bit of their enthusiasm after
realizing that some cyst stages, such as
CE2 and CE3b, are quite tedious to
needle with too many compartments to
be individually approached. But most
importantly, these stages tend to relapse
after PAIR. It remains to be seen whether
large modified catheterization techniques
can substitute for PAIR in these stages.
Over the past decade, several studies
have been published suggesting that med-
ical therapy (mebendazole, albendazole)
could be an alternative to invasive treat-
ment options in patients with uncompli-
cated cysts, broadening the indication for
medical treatment over the years. The
individual studies were all small and
heterogeneity precluded appropriate
meta-analysis. A recently published pooled
analysis of individual patient data collected
from six treatment centres suggests that
the overall efficacy of benzimidazoles has
been overrated [14]. Clinical trials strati-
fied by cyst stage are needed to define the
place of anti-parasitic treatment in the
treatment of CE since it appears that it
works better in some cyst stages (e.g., small
CE1 cysts) than in others. The rate and
nature of side effects of prolonged appli-
cation of benzimidazole also deserves to be
investigated more rigorously. Other an-
thelmintics, old and new (praziquantel,
nitazoxanide), and combinations of an-
thelmintics (e.g., albendazole plus prazi-
quantel) need to be properly investigated,
too.
Though so far not systematically stud-
ied, experience with leaving certain cysts
completely alone and only following them
up over years, points to a fourth managing
option, watch & wait. Apart from being
biologically plausible, long term follow-up
of patients with CE4 and CE5 cysts in
anatomically silent corners of the body
looks good. This holds great promise for
patients in whom cysts have reached this
Figure 1. Life cycle of Echinococcus granulosus in a community of the Middle Atlas
region, Morocco. (We thank M. Kachani, College of Veterinary Medicine, Western University of
Health Sciences, for the pictures.)
doi:10.1371/journal.pntd.0001146.g001
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ically studied.
Reasons for Arrested Progress
in CE
Difficult, chronic diseases with a low
case fatality rate clustering in poor rural
areas are particularly ‘‘unattractive’’ to
researchers and funders who depend on
quick results to maintain the momentum
of their activities. CE shares this fate with
other communicable diseases, such as
neurocysticercosis and Buruli disease.
Health services also turn a blind eye on
them since they plainly lack the means to
manage patients with complex diseases
such as CE appropriately. This is reflected
in the low attention national and interna-
tional institutions are paying to CE despite
its substantial global burden, which is
estimated at over 1 million DALYs per
year [15,16]. Additionally, due to its global
distribution pattern, CE is not taking
advantage of the attention that is being
paid to ‘‘tropical’’ diseases. Interestingly,
CE never made it to the list of the ‘‘TDR
diseases’’ (from the WHO Special Pro-
gramme for Research and Training in
Tropical Diseases). The scarcity of re-
sources and lack of momentum leads
research to develop in niches with research
communities too small to plan and con-
duct projects on a scale that allows
conclusive answering of the relevant ques-
tions on efficacy, effectiveness, adverse
reactions, and costs of a given treatment
in comparison to other options. Currently
available data arise from a multitude of
small underpowered studies carried out
over years, leading to contradicting results
and recommendations, and, consequently,
to controversies and difficulties (e.g.,
randomization) when planning appropri-
ately designed clinical trials.
What Do We Need to Improve
CE Management in the Short
Term?
Here is a most clinically neglected
parasitic disease that urgently needs atten-
tion. A valuable tool for diagnosing,
staging, and following up patients, ultra-
sound, is readily available. Four manage-
ment procedures, surgery, percutaneous
sterilization techniques, anti-parasitic
treatment, and watch & wait, have
‘‘evolved’’ over decades, and been recently
summarized [4], but without adequate
comparative evaluation of efficacy, effec-
tiveness, rate of adverse events, relapse
rates, and cost. Clinical decision making is
on even shakier ground for extrahepatic
and extrapulmonary locations, which are
rarer (see [4] for a list of extrahepatic and
extrapulmonary locations with related
treatments), and numbers needed to build
comparative trials hard to come by. There
is an obligation to put at least what we
have on an appropriate evidence base by
conducting comparative clinical trials at
the scale and quality that allow answering
these important questions. As one of the
expected results, clear criteria for the
watch & wait option alone might already
save a substantial proportion of patients
from unnecessary interventions and save
health services money. Difficult chronic
diseases clustering in poor rural areas need
intelligent, creative approaches, and this
one urgently needs operational research
incorporating the particularities of re-
source-poor settings into consideration.
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